SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

SAN

97.33

-3.65%↓

EI

247.8

-2.25%↓

SHL.DE

46.16

-4.11%↓

ARGX

525.4

-3.63%↓

FRE

38.85

-1.99%↓

Search

Innate Pharma SA

Closed

1.8 -1.85

Overview

Share price change

24h

Current

Min

1.7

Max

1.856

Key metrics

By Trading Economics

Income

-25M

Sales

12M

Profit margin

-200.599

Employees

181

EBITDA

-26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+137.75% upside

Market Stats

By TradingEconomics

Market Cap

159M

Previous open

3.65

Previous close

1.8

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Innate Pharma SA Chart

Past performance is not a reliable indicator of future results.

Related News

3 Apr 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 Apr 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 Apr 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 Apr 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 Apr 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 Apr 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 Apr 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 Apr 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 Apr 2025, 21:43 UTC

Top News
Earnings

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 Apr 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 Apr 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Apr 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 Apr 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 Apr 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 Apr 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 Apr 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Apr 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 Apr 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 Apr 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 Apr 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 Apr 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 Apr 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 Apr 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 Apr 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 Apr 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 Apr 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 Apr 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 Apr 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 Apr 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Innate Pharma SA Forecast

Price Target

By TipRanks

137.75% upside

12 Months Forecast

Average 4.398 EUR  137.75%

High 5.7 EUR

Low 3.1 EUR

Based on 2 Wall Street analysts offering 12 month price targets forInnate Pharma SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

1.85 / 1.88Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.